Regulatory2026-06-01

LYTENAVA (bevacizumab-vikg) / ONS-5010 - (NORSE EIGHT)

Outlook Therapeutics Inc.OTLK
Indication
Wet age-related macular degeneration (wet AMD)
Stage
phase4
Event
Submission